Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue SUPPL., 1999, Pages

  So, Samuel K ^a   Esquivel, Carlos O ^a   Imperial, Joanne C ^a   Garcia, Gabriel ^a   Monge, Humberto ^a   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asian; Hepatitis B cirrhosis; Liver transplantation; Survival

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; FAMCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; LOBUCAVIR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; ASIAN; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT INFECTION; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

EID: 0033017787     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
2. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1091; 13: 150-7.
3. Benner KG, Lee RG, Keeffe EB et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992; 103: 1307-12.
4. Fang JWS, Tung FYT, Davis GL et al. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant. Gastroenterology 1993; 105: 901-4.
5. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842-7.
6. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-64.
7. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-33.
8. So SKS, Esquivel CO, Imperial J, Garcia G, Concepcion W, Keeffe EB. Liver transplantation for HBeAg-positive chronic HBV cirrhosis. Hepatology 1996; 24: 581A.
9. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immunoglobulin (HBIG) prophylaxis after liver transplantation. Clin. Transplant. 1996; 10: 663-7.
10. Jurim O, Martin P, Shaked A et al. Liver transplantation for chronic hepatitis B in Asians. Transplantation 1994; 57: 1393-411.
11. Ho BM, So SK, Esquivel CO, Keeffe EB. Liver transplantation in Asian patients with chronic hepatitis B. Hepatology 1997; 25: 223-5.
12. Gish RG, Keeffe E, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J. Hepatol. 1995; 22: 257-62.
13. Lai CL, Chien RN, Leun NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl J. Med. 1908; 339: 61-8.
14. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
15. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 1615-21.
16. Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456-62.
17. Perrillo R, Rakela J, Martin P et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation. Hepatology 1997; 26: 260A.
18. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
19. Tipples GA, Ma MM, Fischer KP et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
20. Terrault NA, Wright TL, Roberts JP, Ascher NL. Combined short-term hepatitis B immunoglobulin and long-term lamivudine versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 1998; 28: 389A.
21. Crippin J, Foster B, Carlen S et al. Retransplantation in hepatitis B. A multicenter experience. Transplantation 1994; 57: 823-6.
22. Ben-Ari Z, Shmueli D, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63: 393-6.
23. Krüger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant. Surg. 1996; 2: 253-62.
24. Gish RG, Lau JYN, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1-7.
25. Ishitani M, McGory R, Dickson R et al. Retransplantation of patients with severe post-transplant hepatitis B in the first allograft. Transplantation 1997; 64: 410-14.